A360
Key Takeaways✦ Atlas AI
01
A specific lot of Xanax XR 3mg tablets was recalled nationwide due to failing dissolution tests, meaning the medication might not release its active ingredient effectively.
02
This recall is classified as Class II, indicating a low risk of serious health consequences, but primarily concerns reduced therapeutic efficacy for patients relying on the drug.
03
Patients are advised to consult healthcare providers for replacement prescriptions rather than abruptly stopping the medication, to avoid potential withdrawal symptoms.
Atlas AI
A specific lot of Xanax XR (alprazolam extended-release tablets), 3-milligram dosage, has been voluntarily recalled nationwide. The recall, initiated on March 17, affects lot number 8177156, distributed in 60-tablet bottles.
The recall was prompted by the product's failure to meet dissolution specifications during quality control testing. This issue may result in the medication not releasing the active ingredient effectively, potentially reducing its therapeutic impact.
Regulatory authorities classify this as a Class II recall, indicating a low probability of serious adverse health consequences. The primary risk is reduced efficacy, not direct harm.
Patients are advised not to discontinue medication abruptly due to potential withdrawal symptoms. Healthcare providers should be consulted for guidance on replacement prescriptions.
The recall remains ongoing.
